Amy Fox - Evolus Vice President of Human Resources
| EOLS Stock | USD 11.50 0.20 1.71% |
President
Ms. Amy Marinne Fox is Vice President of Human Resources of the Company. Ms. Fox has over 20 years of experience building high performing, agile organizations. Ms. Fox previously served as Vice President, Human Resources of Orexigen Therapeutics, where she led the design of employee retention programs and global HR capabilities to meet organizational demands with system implementations, metrics and process improvements. Prior to Orexigen, she served as Director of Human Resources at Synteract, a global Clincal Research Organization specializing in the delivery of clinical trial solutions across multiple therapeutic areas. Previously, she served as a Human Resources Manager at Robbins Arroyo, a boutique law firm specializing in securities litigation since 2018.
| Tenure | 6 years |
| Address | 520 Newport Center Drive, Newport Beach, CA, United States, 92660 |
| Phone | (949) 284-4555 |
| Web | https://www.evolus.com |
Evolus Management Efficiency
The company has return on total asset (ROA) of (0.123) % which means that it has lost $0.123 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (12.7929) %, meaning that it created substantial loss on money invested by shareholders. Evolus' management efficiency ratios could be used to measure how well Evolus manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 3.13 in 2024, whereas Return On Tangible Assets are likely to drop (0.54) in 2024. At this time, Evolus' Total Assets are comparatively stable compared to the past year. Intangibles To Total Assets is likely to gain to 0.57 in 2024, whereas Non Current Assets Total are likely to drop slightly above 63.4 M in 2024.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Jason Shandell | Amphastar P | 44 | |
| Stephen Carey | ANI Pharmaceuticals | 53 | |
| David Gaffin | Alkermes Plc | 52 | |
| Jacob Liawatidewi | Amphastar P | 44 | |
| Lisa Escudero | Phibro Animal Health | 62 | |
| Rong Zhou | Amphastar P | 59 | |
| Christopher Heye | Prestige Brand Holdings | 53 | |
| Rob Aukerman | Phibro Animal Health | 66 | |
| Ramon Fuenmayor | Phibro Animal Health | N/A | |
| Andrew Satlin | Intracellular Th | 62 | |
| Craig Hopkinson | Alkermes Plc | 49 | |
| Robert Davis | Intracellular Th | 73 | |
| Juan Sanchez | Intracellular Th | 53 | |
| Samson Li | Phibro Animal Health | 52 | |
| Charlotte Arnold | ANI Pharmaceuticals | 49 | |
| Kevin OKeeffe | Collegium Pharmaceutical | N/A | |
| Joseph Ciaffoni | Collegium Pharmaceutical | 53 | |
| Michael Landine | Alkermes Plc | 70 | |
| Michael Giambalvo | Phibro Animal Health | N/A | |
| Alison Fleming | Collegium Pharmaceutical | 43 | |
| Shane Cooke | Alkermes Plc | 54 | |
Management Performance
| Return On Equity | -12.79 | ||||
| Return On Asset | -0.12 |
Evolus Inc Leadership Team
Elected by the shareholders, the Evolus' board of directors comprises two types of representatives: Evolus inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Evolus. The board's role is to monitor Evolus' management team and ensure that shareholders' interests are well served. Evolus' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Evolus' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Karah Parschauer, Director | ||
| Lauren Silvernail, CFO, Executive Vice President - Corporate Development | ||
| Jessica Novak, Senior Resources | ||
| Michael Jafar, Chief Marketing Officer | ||
| Kristine Romine, Independent Director | ||
| Peter Farrell, Director | ||
| Amy Fox, Vice President of Human Resources | ||
| Crystal Muilenburg, Vice President Corporate Communications and Public Relations | ||
| CCFP DipSportMed, Chief RD | ||
| Sandra Beaver, Chief Officer | ||
| Robert Hayman, Independent Director | ||
| Bosun Hau, Independent Director | ||
| Vikram Malik, Chairman of the Board | ||
| Murthy Simhambhatla, President CEO, Director | ||
| Brian Johnston, IR Contact Officer | ||
| Christopher Marmo, COO | ||
| Kurt Knab, Vice President of Sales | ||
| Rui Avelar, Chief Medical Officer | ||
| Alejandro Sabad, Vice President - Operations | ||
| Tomoko YamagishiDressler, Chief Officer | ||
| David Gill, Director | ||
| David Erickson, VP Relations | ||
| David Moatazedi, President CEO, Director | ||
| Jeffrey Plumer, General Counsel | ||
| Simone Blank, Director | ||
| Nareg Sagherian, Head Communications |
Evolus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Evolus a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -12.79 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.31) % | ||||
| Operating Margin | (0.08) % | ||||
| Current Valuation | 742.81 M | ||||
| Shares Outstanding | 61.5 M | ||||
| Shares Owned By Insiders | 13.05 % | ||||
| Shares Owned By Institutions | 77.16 % | ||||
| Number Of Shares Shorted | 4.65 M | ||||
| Price To Earning | (5.55) X |
Pair Trading with Evolus
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Evolus position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Evolus will appreciate offsetting losses from the drop in the long position's value.Moving together with Evolus Stock
| 0.7 | EFTR | Effector Therapeutics Financial Report 14th of May 2024 | PairCorr |
Moving against Evolus Stock
| 0.61 | ELYM | Eliem Therapeutics | PairCorr |
| 0.56 | ACB | Aurora Cannabis Trending | PairCorr |
The ability to find closely correlated positions to Evolus could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Evolus when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Evolus - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Evolus Inc to buy it.
The correlation of Evolus is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Evolus moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Evolus Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Evolus can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evolus Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Complementary Tools for Evolus Stock analysis
When running Evolus' price analysis, check to measure Evolus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evolus is operating at the current time. Most of Evolus' value examination focuses on studying past and present price action to predict the probability of Evolus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evolus' price. Additionally, you may evaluate how the addition of Evolus to your portfolios can decrease your overall portfolio volatility.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |
Is Evolus' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evolus. If investors know Evolus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evolus listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.08) | Revenue Per Share 3.55 | Quarterly Revenue Growth 0.398 | Return On Assets (0.12) | Return On Equity (12.79) |
The market value of Evolus Inc is measured differently than its book value, which is the value of Evolus that is recorded on the company's balance sheet. Investors also form their own opinion of Evolus' value that differs from its market value or its book value, called intrinsic value, which is Evolus' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evolus' market value can be influenced by many factors that don't directly affect Evolus' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evolus' value and its price as these two are different measures arrived at by different means. Investors typically determine if Evolus is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evolus' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.